May 7, 2018 10:09 AM EDT
News Briefing

Al­ler­gan aes­thet­ics chief David Moataze­di be­comes CEO of Evo­lus; CARB-X in­vests $6.2M in­to Melin­ta's next-gen an­tibi­otics

John Carroll

Editor & Founder

→ Al­ler­gan aes­thet­ics chief David Moataze­di is leav­ing to take the helm of Evo­lus, a much small­er biotech de­vel­op­ing a ri­val to Botox. Evo­lus’ …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Lil­ly’s oral SERD makes strides in breast can­cer with Phase 3 da­ta

The End­points 100: The biotech in­dus­try braces for Trump 2.0

Ex­clu­sive: Bain-backed mus­cu­loskele­tal biotech rais­es $120M for trio of clin­i­cal-stage bi­o­log­ics

Ace­lyrin says good­bye to the drug that got it a $540M IPO in 2023

Chro­ma, Nvel­op merge to form nChro­ma Bio, rais­ing $75M to en­ter the clin­ic

sponsored

The key to faster, more im­pact­ful re­search? Put pa­tients in the dri­ver’s seat

A service from the Financial Times